STAMFORD, Conn. – Curaleaf Holdings is making its most tangible move yet toward a major U.S. stock exchange listing. The Stamford, Connecticut-based multistate operator announced May 26 that a 1-for-3 reverse stock split of its subordinate voting shares is expected to take effect on or about June 5.
The mechanics of the 1-for-3 stock split
The mechanics are straightforward:
- The ratio: Every three pre-consolidation shares will become one post-consolidation share.
- Share reduction: The company’s outstanding subordinate voting shares will drop from about 698.7 million to roughly 232.9 million.
- The rationale: The move is designed to push the per-share price to levels required by major U.S. exchanges, a prerequisite for any uplisting bid.
Positioning for a U.S. exchange listing
Curaleaf’s board approved the consolidation in consultation with major U.S. stock exchanges, with the goal of enabling the company to uplist as soon as the regulatory opportunity becomes available. Beyond satisfying exchange price thresholds, the split also is intended to push Curaleaf’s shares above trading minimums enforced by some retail brokerage firms and broaden participation from institutional investors, many of whom remain restricted from cannabis equities by compliance concerns tied to the plant’s federal status.
The impact of federal cannabis rescheduling
That status, at least for state-licensed medical cannabis and FDA-approved cannabis products, changed in late April, when Acting U.S. Attorney General Todd Blanche moved cannabis from Schedule I to Schedule III under the Controlled Substances Act. The status of adult-use products is pending the outcome of a formal Drug Enforcement Administration hearing scheduled to begin June 29.
Boris Jordan, Curaleaf’s chairman and chief executive officer, pointed to the proceedings as the catalyst driving his company’s stock-split maneuver.
“Rescheduling of medical cannabis has created a potential pathway toward uplisting to a major U.S. exchange, and we’re now more prepared than ever,” he said. “With a hearing on the full rescheduling of cannabis expected to end in July, and U.S. Treasury guidance supporting the normalization of the industry forthcoming, we believe there will soon be greater clarity around the regulatory and tax framework for our industry.”
Jordan framed the reverse stock split as preparation for a window the company intends to move through quickly.
“These developments should improve access to capital, broaden the investor base, and further legitimize cannabis in the public markets,” he said. “We are preparing today to move quickly and decisively when that opportunity comes into view.”
What Curaleaf’s stock consolidation means for shareholders
The split has received conditional approval from the Toronto Stock Exchange (TSX), where Curaleaf currently trades under the symbol CURA. The company also will continue trading on the OTCQX market under the symbol CURLF. Fractional shares will not be issued; any fractional entitlement resulting from the consolidation will be rounded to the nearest whole share. Outstanding stock options and other convertible securities will be adjusted proportionately.
Shareholders who hold shares through a broker or intermediary will see the adjustment applied automatically. Registered shareholders will receive a letter of transmittal from transfer agent Odyssey Trust Company with instructions for exchanging pre-split certificates.
Rescheduling strategy and broader market signals
The move signals Curaleaf — which operates across medical and adult-use markets and has international operations in Europe, Canada, and Australasia — is treating federal rescheduling as a potentially actionable near-term event. Whether the upcoming hearing delivers the clarity Jordan anticipates remains to be seen, but the share consolidation puts the company in position to act quickly if a path to a major U.S. exchange opens.
